Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis

Summary

It has been shown that type 2 diabetes (DM) is associated with enhanced thrombin generation and formation of denser fibrin clots of reduced lysability. We sought to investigate the impact of diabetes duration versus glycaemia control on fibrin clot phenotype and its determinants in type 2 diabetic patients. In 156 consecutive Caucasian patients with type 2 diabetes we investigated ex vivo thrombin generation, fibrinolytic proteins, along with plasma fibrin clot permeation (K_s ), compaction, turbidity, and efficiency of tissue plasminogen activator (t-PA)-mediated fibrinolysis. Patients with longer diabetes duration (>5 years, median; n=68) had higher peak thrombin generation (+16.3%, p<0.001), plasminogen activator inhibitor-1 (PAI-1) antigen (+14.8%, p=0.001), t-PA antigen (+13.9%, p=0.002) compared with those with duration ≤5 years (n=88). No such differences were observed between patients with inadequate glycaemic control, defined as glycated haemoglobin (HbA_1C) >6.5% (48 mmol/mol) (n=77), versus those with HbA_1C ≤6.5% (n=79). Fibrinogen, thrombin-activatable fibrinolysis inhibitor antigen, plasminogen and soluble thrombomodulin were unaffected by disease duration or glycaemia control. Lower clot permeability, longer clot lysis, and higher maximum D-dimer levels released from clots (all p<0.05 after adjustment for fibrinogen, age, body mass index, insulin, acetylsalicylic acid treatment, and HbA1c or diabetes duration) were also observed in patients with diabetes duration >5 years and those with HbA_1C >6.5%. We conclude that prolonged duration of type 2 diabetes is associated with increased thrombin formation, hypofibrinolysis, and prothrombotic fibrin clot phenotype. The impact of disease duration on coagulation is different and stronger than that observed during inadequate glycaemia control.

Keywords

Diabetes - glycaemic control - fibrin clot - fibrinolysis - thrombin

• References

• 1 Stratmann B, Tschoepe D. Atherogenesis and atherothrombosis - focus on diabetes mellitus.. Best Pract Res Clin Endocrinol Metab 2009; 23: 291-303.
• 2 Haffner SM, Lehto S, Ronnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.. N Engl J Med 1998; 350: 229-234.
• 3 Undas A. Acquired dysfibrinogenemia in atherosclerotic vascular disease.. Pol Arch Med Wewn 2011; 121: 310-318.
• 4 Collet JP, Allali Y, Lesty C. et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis.. Arterioscler Thromb Vasc Biol 2006; 26: 2567-2573.
• 5 Undas A, Wiek I, Stepien E. et al. Hyperglycaemia is associated with enhanced thrombin formation, platelet activation and fibrin clot resistance to lysis in patients with acute coronary syndrome.. Diabetes Care 2008; 31: 1590-1595.
• 6 Undas A, Szuldrzynski K, Stepien E. et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress.. Atherosclerosis 2008; 196: 551-558.
• 7 Rooth E, Wallen NH, Blombäck M. et al. Decreased fibrin network permeability and impaired fibrinolysis in the acute and convalescent phase of ischaemic stroke.. Thromb Res 2011; 127: 51-56.
• 8 Undas A, Slowik A, Wolkow P. et al. Fibrin clot properties in acute ischaemic stroke: relation to neurological deficit.. Thromb Res 2010; 125: 357-361.
• 9 Undas A, Nowakowski T, Ciesla-Dul M. et al. Abnormal plasma fibrin clot characteristics are associated with worse clinical outcome in patients with peripheral arterial disease and thromboangiitis obliterans.. Atherosclerosis 2011; 215: 481-486.
• 10 Meltzer ME, Lisman T, de Groot PG. et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.. Blood 2010; 116: 113-121.
• 11 Undas A, Zawilska K, Ciesla-Dul M. et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives.. Blood 2009; 114: 4272-4278.
• 12 Jorneskog G, Egberg N, Fagrell B. et al. Altered properties of fibrin gel structure in patients with IDDM.. Diabetologia 1996; 39: 1519-1523.
• 13 Dunn E, Philippou H, Ariéns RAS. et al. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes melli- tus.. Diabetologia 2006; 49: 1071-1080.
• 14 Dunn E, Ariéns RAS, Grant PJ. The influence of type 2 diabetes on clot structure and function.. Diabetologia 2005; 48: 1198-1206.
• 15 Alzahrani SH, Aijan RA. Coagulation and fibrinolysis in diabetes.. Diab Vasc Dis Res 2010; 7: 260-273.
• 16 Undas A, Ariéns RAS. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolism diseases.. Arterioscler Thromb Vasc Biol 2011; 31: e88-99.
• 17 Pieters M, Covic N, van der Westhuizen FH. et al. Glycaemic control improves fibrin network characteristics in type 2 diabetes. A purified fibrinogen model.. Thromb Haemost 2008; 99: 691-700.
• 18 Jorneskog G, Hansson LO, Wallen NH. et al. Increased plasma fibrin gel porosity in patients with type I diabetes during continuous subcutaneous insulin infusion.. J Thromb Haemost 2003; 1: 1195-1201.
• 19 ACCORD Study Group.. Long-term effects of intensive glucose lowering on cardiovascular outcomes.. N Engl J Med 2011; 364: 818-828.
• 20 Bloomgarten ZT. Diabetes and cardiovascular disease.. Diabetes Care 2011; 31: e24-e30.
• 21 Ceriello A, Ihnat MA, Thorpe JE. The “Metabolic Memory”: Is more than just tight glucose control necessary to prevent diabetic complications?. J Clin Endocrinol Metab 2009; 94: 410-415.
• 22 Tesfaye S, Boulton AJM, Dyck PJ. et al. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments.. Diabetes Care 2010; 33: 2285-2293.
• 23 Stepien E, Plicner D, Branicka A. et al. Factors influencing thrombin generation measured as thrombin-antithrombin complexes levels and using calibrated automated thrombogram in patients with advanced coronary artery disease.. Pol Arch Med Wew 2007; 117: 297-305.
• 24 Lisman T, Leebeek FWG, Mosnier LO. et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibri-nolysis.. Gastroenterology 2001; 121: 131-139.
• 25 Williams S, Fatah K, Ivert T. et al. The effect of acetyl salicylic acid on fibrin gel lysis by tissue plasminogen activator.. Blood Coagul Fibrinolysis 1995; 6: 718-725.
• 26 Undas A, Celinska-Lowenhoff M, Lowenhoff T. et al. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease.. J Thromb Haemost 2006; 4: 1029-1036.
• 27 Mills JD, Ariens RA, Mansfield MW, Grant PJ. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease.. Circulation 2002; 106: 1938-1942.
• 28 Meltzer ME, Lisman T, Doggen CJ. et al. Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis.. PLoS Med 2008; 5: e97.
• 29 Pankiw-Bembenek O, Zalewski J, Goralczyk T. et al. A history of early stent thrombosis is associated with prolonged clot lysis time.. Thromb Haemost 2012; 107: 513-520.
• 30 Siegerink B, Meltzer ME, de Groot PG. et al. Clot lysis time and the risk of myocardial infarction and ischaemic stroke in young women; results from the RATIO case-control study.. Br J Haematol 2012; 156: 252-258.
• 31 Bochenek M, Zalewski J, Sadowski J. et al. Type 2 diabetes as a modifier of fibrin clot properties in patients with coronary artery disease.. J Thromb Thrombolysis 2013; 35: 264-270.
• 32 Wannamethee SG, Sattar N, Rumley A. et al. Tissue plasminogen activator, von Willebrand factor, and risk of type 2 diabetes in older men.. Diabetes Care 2008; 31: 995-1000.
• 33 Schneider DJ, Sobel BE. PAI-1 and diabetes. A journey from the bench to the bedside.. Diabetes Care 2012; 35: 1961-1967.
• 34 Al Dieri R, de Laat B, Hemker HC. Thrombin generation: What have we learned?. Blood Rev 2012; 26: 197-203.
• 35 Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus.. Diabeto-logia 2008; 51: 385-390.